Psychiatry Grand Rounds

Webex Link: https://ttuhscep.webex.com/ttuhscep/j.php?MTID=m67419a1f2962105025f35da111420a05
Webinar number: 2537 304 2453
Panelist password: yMCfhKAa736 (96234522 from phones and video systems)

Friday, Oct. 6, 2023
Noon – 1 p.m.

Cognitive Impairment Associated With Schizophrenia: A Focus On Pathophysiology, Burden of Disease, and Clinical Management

Presented by:

Deepak Cyril D’Souza, M.D.
Albert E. Kent Endowed Professor of Psychiatry
Yale University School of Medicine
New Haven, Connecticut

Objectives: Upon completion of this session, the participant should be able to:

- Recognize the burden of cognitive impairment associated with schizophrenia (CIAS) in patients.
- Differentiate cognitive impairment from other positive or negative symptoms associated with schizophrenia.
- Assess how ongoing developments in clinical research may help address current limitations in the management of CIAS.

Accreditation: The Texas Tech University Health Sciences Center El Paso Paul L. Foster School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The Texas Tech University Health Sciences Center El Paso Paul L. Foster School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To claim CME credit, participants must log on using their full name and remain logged on for a minimum of 75%, if not the entirety of the CME activity. Attendance logs with entry and exit time stamps will be used to validate attendance requirements.

It is the policy and practice of the Texas Tech University Health Sciences Center El Paso Office of Continuing Medical Education to identify, mitigate and disclose all relevant financial relationships with ineligible companies prior to the activity.

All planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing health care products used by or on patients.

Deepak Cyril D’Souza, M.D. Hs disclosed that he is conducting research studies with Boehringer Ingelheim, Biogen and Cerevel. He is an advisor for Shulgin Institute, a consultant for Biohaven and an educational content developer for France Foundation.

All relevant financial relationships have been mitigated.

The Office of CME reserves the right to cancel this activity in the event of unforeseen or extenuating circumstances.